Brought to you by 
Pfizer to help develop and market Eisai's Alzheimer's drug
24 May 2013
Executive Summary
Eisai Co. and Pfizer will collaborate on development and marketing of Eisai's E2020 once-daily Alzheimer's drug. A joint committee will also plan development of Pfizer's CP-118,954 (Phase II) and other products for treating dementia.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer to help develop and market Eisai's Alzheimer's drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice